CONTRAFECT Corp
contrafect.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 14, 2023. Its latest SEC filing is a SCHEDULE 13G from Aug 14, 2025.
10-Q for Q3 FY2023, filed Nov 14, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops experimental medicines, including lysins and amurin peptides, to treat life-threatening infections caused by antibiotic-resistant bacteria.
10-K for FY2022, filed Mar 31, 2023
How Did They Make Money?
No revenue was reported.
10-K for FY2022, filed Mar 31, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 14, 2023
−$5.4MView ↗
- ▼ −69% (Loss)
- vs −$17.1M in Q3 FY2022
-
Dec 5, 2023
ContraFect ceased operations and filed for Chapter 7 bankruptcy
A trustee will take control of the company's assets and liabilities, which will be liquidated; the CEO, CFO and other officers resigned.
Sources
8-K, filed Dec 5, 2023
On December 4, 2023, ContraFect Corporation (the “Company”) ceased operations and filed a voluntary petition for relief under the…View ↗
-
Nov 15, 2023
The CEO resigned as the company reduced its workforce
The restructuring cut the workforce from 23 employees to five employees.
Sources
8-K, filed Nov 15, 2023
On November 15, 2023, ContraFect Corporation (the “Company”) implemented a restructuring plan resulting in a reduction to the Company’s…View ↗
-
Nov 8, 2023
Nasdaq decided to delist the company's common stock
Nasdaq said trading would be suspended effective at the opening of trading on November 9, 2023.
Sources
8-K, filed Nov 8, 2023
On November 7, 2023, the Company received a determination letter (the “Delisting Notification”) from the Nasdaq Hearings Advisor stating…View ↗
Exebacase's target infections
The earlier report centered exebacase on bloodstream infections; the latest says that trial was stopped and describes an ongoing study for chronic knee-joint infections.
10-K for FY2019, filed Mar 18, 2020 10-K for FY2022, filed Mar 31, 2023
Who Did They Compete With?
Competes with Osteal Therapeutics, Peptilogics, Adaptive Phage Therapeutics, Armata Pharmaceuticals, Orthobond, Aridis Pharmaceuticals, Atox Bio, Biotest, MedImmune, XBiotech, Genentech, iNtRon Biotechnology, and Roivant Sciences
10-K for FY2022, filed Mar 31, 2023Based on our reasonable search of available data, there are only four other companies in the U.S. pursuing potential treatments in clinical…View ↗
Loading...
